Wednesday, bluebird bio, Inc. (BLUE) announced the appointment of James Sterling as chief financial officer.
Sterling will assume the role on June 10, succeeding Chris Krawtschuk, who has served as bluebird bio's chief financial officer since 2022.
Most recently, Sterling held the position of chief financial officer at Renalytix plc, a diagnostics company specializing in the clinical management of kidney disease.
In pre-market activity on the Nasdaq, the shares are trading at $0.92, down 2.14%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.